PCL

피씨엘 · 241820

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$12.2M (₩16.8B)

Overview

PCL makes diagnostic test kits and instruments that detect infectious diseases, cancers, and other conditions from a blood sample, without surgery or a laboratory send-out.

Its products are used to screen blood supplies for high-risk viruses and to run point-of-care tests (rapid bedside or clinic tests) for conditions ranging from influenza to several cancer types, and it also supplies diagnostic kits for companion animals. Listed on KOSDAQ, Korea's tech and small-cap board, the company has expanded beyond diagnostics into supplying medicines for chronic diseases and into antimicrobial film materials and cosmetics derived from its core materials technology.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2024
Revenue · FY2024
US$903K
▼ −85.2% YoY
Operating profit · FY2024
−US$19.6M
Loss widened
Net income · FY2024
−US$38.3M
Loss widened

Revenue

  • FY2023US$6.1M
  • FY2024US$903K

Operating profit

  • FY2023−US$11.7M
  • FY2024−US$19.6M

Net income

  • FY2023−US$14.7M
  • FY2024−US$38.3M

Key ratios (FY2024)

ROE
-742.6%
Debt/Eq
203.2%
Op. margin
-2175.4%
Net margin
-4240.5%
Rev. YoY
▼ −85.2%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.